$LXRX LX9211 has received fast track designation from the U.S. Food and Drug Administration for the development in diabetic peripheral neuropathic pain. Found this while looking for anything positive today
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.